WHO guide on the economic evaluation of influenza vaccination

Anthony T Newall, Nathorn Chaiyakunapruk, Philipp Lambach, Raymond C W Hutubessy, Anthony T Newall, Nathorn Chaiyakunapruk, Philipp Lambach, Raymond C W Hutubessy

Abstract

Influenza is responsible for substantial morbidity and mortality across the globe, with a large share of the total disease burden occurring in low- and middle-income countries (LMICs). There have been relatively few economic evaluations assessing the value of seasonal influenza vaccination in LMICs. The purpose of this guide is to outline the key theoretical concepts and best practice in methodologies and to provide guidance on the economic evaluation of influenza vaccination in LMICs. It outlines many of the influenza vaccine-specific challenges and should help to provide a framework for future evaluations in the area to build upon.

Keywords: guidelines; influenza vaccines; vaccine economics.

© 2017 The Authors. Influenza and Other Respiratory Viruses Published by John Wiley & Sons Ltd.

Figures

Figure 1
Figure 1
Elements of the influenza disease burden that may/may not be estimated using WHO's A manual for estimating disease burden associated with seasonal influenza12

References

    1. Nair H, Brooks WA, Katz M, et al. Global burden of respiratory infections due to seasonal influenza in young children: a systematic review and meta‐analysis. Lancet. 2011;378:1917‐1930.
    1. Jit M, Newall AT, Beutels P. Key issues for estimating the impact and cost‐effectiveness of seasonal influenza vaccination strategies. Hum Vaccin Immunother. 2013;9:834‐840.
    1. Peasah SK, Azziz‐Baumgartner E, Breese J, Meltzer MI, Widdowson MA. Influenza cost and cost‐effectiveness studies globally – a review. Vaccine. 2013;31:5339‐5348.
    1. Newall AT, Jit M, Beutels P. Economic evaluations of childhood influenza vaccination: a critical review. Pharmacoeconomics. 2012;30:647‐660.
    1. Mauskopf J, Chirila C, Masaquel C, et al. Relationship between financial impact and coverage of drugs in Australia. Int J Technol Assess Health Care. 2013;29:92‐100.
    1. De Waure C, Veneziano MA, Cadeddu C, et al. Economic value of influenza vaccination. Hum Vaccin Immunother. 2012;8:78‐88.
    1. Gatwood J, Meltzer MI, Messonnier M, et al. Seasonal influenza vaccination of healthy working‐age adults: a review of economic evaluations. Drugs. 2012;72:35‐48.
    1. Ott JJ, Klein Breteler J, Tam JS, et al. Influenza vaccines in low and middle income countries: a systematic review of economic evaluations. Hum Vaccin Immunother. 2013;9:1500‐1511.
    1. World Health Organization . WHO Guidance on the economic evaluation of influenza vaccination. Geneva: World Health Organization; 2016.
    1. World Health Organization . Principles and Considerations for Adding a Vaccine to a National Immunization Programmes. Geneva: World Health Organization; 2014.
    1. Warren‐Gash C,Smeeth L, Hayward AC. Influenza as a trigger for acute myocardial infarction or death from cardiovascular disease: a systematic review. Lancet Infect Dis. 2009;9:601‐610.
    1. World Health Organization . WHO A Manual for Estimating Disease Burden Associated With Seasonal Influenza. Geneva: World Health Organization; 2015. .
    1. Thompson WW, Weintraub E, Dhankhar P, et al. Estimates of US influenza‐associated deaths made using four different methods. Influenza Other Respir Viruses. 2009;3:37‐49.
    1. Nicoll A, Ciancio BC, Lopez Chavarrias V, et al. Influenza‐related deaths – available methods for estimating numbers and detecting patterns for seasonal and pandemic influenza in Europe. Euro Surveill. 2012;17: pii: 20162.
    1. Newall AT, Viboud C, Wood JG. Influenza‐attributable mortality in Australians aged more than 50 years: a comparison of different modelling approaches. Epidemiol Infect. 2010;138:836‐842.
    1. de Francisco Shapovalova N, Donadel M, Jit M, Hutubessy R. A systematic review of the social and economic burden of influenza in low‐ and middle‐income countries. Vaccine. 2015;33:6537‐6544.
    1. World Health Organization . WHO Guide for Standardization of Economic Evaluations of Immunization Programmes. Geneva: World Health Organization; 2008.
    1. World Health Organization . WHO A Manual for Estimating the Economic Burden of Seasonal Influenza. Geneva: World Health Organization; 2016. .
    1. Walker DG, Hutubessy R, Beutels P. WHO Guide for standardisation of economic evaluations of immunization programmes. Vaccine. 2010;28:2356‐2359.
    1. World Health Organization . Vaccines against influenza WHO position paper – November 2012. Wkly Epidemiol Rec. 2012;87:461‐476.
    1. SAGE Working Group . Background Paper on Influenza Vaccines and Immunization. Geneva: World Health Organization; 2012.
    1. Newall AT, Kelly H, Harsley S, Scuffham PA. Cost effectiveness of influenza vaccination in older adults: a critical review of economic evaluations for the 50‐ to 64‐year age group. Pharmacoeconomics. 2009;27:439‐450.
    1. Jefferson T, Di Pietrantonj C, Rivetti A, Bawazeer GA, Al‐Ansary LA, Ferroni E. Vaccines for preventing influenza in healthy adults. Cochrane Database Syst Rev. 2010;7:CD001269.
    1. Jefferson T, Di Pietrantonj C, Al‐Ansary LA, Ferroni E, Thorning S, Thomas RE. Vaccines for preventing influenza in the elderly. Cochrane Database Syst Rev. 2010;2:CD004876.
    1. Jefferson T, Rivetti A, Harnden A, Di Pietrantonj C, Demicheli V. Vaccines for preventing influenza in healthy children. Cochrane Database Syst Rev. 2008;2:CD004879.
    1. World Health Organization . WHO Information Sheet: Observed Rates of Vaccine Reactions Influenza Vaccine. Geneva: World Health Organization; 2012.
    1. Keller‐Stanislawski B, Englund JA, Kang G, et al. Safety of immunization during pregnancy: a review of the evidence of selected inactivated and live attenuated vaccines. Vaccine. 2014;32:7057‐7064.
    1. Neuzil KM, Reed GW, Mitchel EF, Simonsen L, Griffin MR. Impact of influenza on acute cardiopulmonary hospitalizations in pregnant women. Am J Epidemiol. 1998;148:1094‐1102.
    1. Hirve S, Lambach P, Paget J, Vandemaele K, Fitzner J, Zhang W. Seasonal influenza vaccine policy, use and effectiveness in the tropics and subtropics – a systematic literature review. Influenza Other Respir Viruses. 2016;10:254‐267.
    1. Kelly H, Newall AT. Mortality benefits of influenza vaccination in elderly people. Lancet Infect Dis. 2008;8:462‐463.
    1. Stephenson I, Nicholson KG. Influenza: vaccination and treatment. Eur Respir J. 2001;17:1282‐1293.
    1. Newall AT, Dehollain JP, Wood JG. Under‐explored assumptions in influenza vaccination models: implications for the universal vaccination of children. Vaccine. 2012;30:5776‐5781.
    1. Newall AT, Dehollain JP, Creighton P, Beutels P, Wood JG. Understanding the cost‐effectiveness of influenza vaccination in children: methodological choices and seasonal variability. Pharmacoeconomics. 2013;31:693‐702.
    1. Charu V, Viboud C, Simonsen L, et al. Influenza‐related mortality trends in Japanese and American seniors: evidence for the indirect mortality benefits of vaccinating school children. PLoS ONE. 2011;6:e26282.
    1. Loeb M, Russell ML, Moss L, et al. Effect of influenza vaccination of children on infection rates in Hutterite communities: a randomized trial. JAMA. 2010;303:943‐950.
    1. Edmunds J, Medley GF, Nokes DJ. Evaluating the cost‐effectiveness of vaccination programmes: a dynamic perspective. Stat Med. 1999;18:3.
    1. Drummond M, Sculpher MJ, Torrance GW, et al. Methods for the Economic Evaluation of Health Care Programmes (3 ed.) Oxford: Oxford University Press; 2005.
    1. Brisson M, Edmunds WJ. Economic evaluation of vaccination programs: the impact of herd‐immunity. Med Decis Making. 2003;23:76‐82.
    1. Kim SY, Goldie SJ. Cost‐effectiveness analyses of vaccination programmes: a focused review of modelling approaches. Pharmacoeconomics. 2008;26:191‐215.
    1. Meeyai A, Praditsitthikorn N, Kotirum S, et al. Seasonal influenza vaccination for children in thailand: a cost‐effectiveness analysis. PLoS Med. 2015;12:e1001829.
    1. Newall AT, Jit M, Hutubessy R. Are current cost‐effectiveness thresholds for low‐ and middle‐income countries useful? Examples from the world of vaccines. Pharmacoeconomics. 2014;32:525‐531.
    1. Praditsitthikorn N, Teerawattananon Y, Tantivess S, et al. Economic evaluation of policy options for prevention and control of cervical cancer in Thailand. Pharmacoeconomics. 2011;29:781‐806.
    1. Bilcke J, Beutels P, Brisson M, Jit M. Accounting for methodological, structural, and parameter uncertainty in decision‐analytic models: a practical guide. Med Decis Making. 2011;31:675‐692.

Source: PubMed

Patrocinadores e Colaboradores

Condições médicas

Intervenções de drogas

3
Se inscrever